Morgan Lewis

Related Publications

11/22/10 Keep One Eye on the Collaboration, And the Other on Exit Events, New Jersey Law Journal (read the article)
November 2002 Changing Environment for Pharma-Biotech Collaborations, New Jersey LifeSciTech , Q4
View all publications

Related News

09/29/14 LMG Life Sciences Praises Morgan Lewis’s Life Sciences Capabilities
Morgan Lewis announces that the firm’s strength in the life sciences industry has been recognized on numerous occasions recently in the Legal Media Group’s LMG Life Sciences 2014 legal guides.
10/03/13 Morgan Lewis Receives 2013 LMG Life Sciences Awards
Morgan Lewis was named Healthcare Pricing and Reimbursement Firm of the Year at the inaugural LMG Life Sciences awards ceremony.
09/24/09 Morgan Lewis Advises LEO Pharma on $1 Billion Acquisition
Morgan Lewis represented LEO Pharma in the $1 billion acquisition of exclusive product licensing rights and inventories from LEO Pharma by Warner Chilcott plc.
View all news

Emerging Business Tools

visit the Entrepreneur Resource Headquarters
Photo of  David G. Glazer

honors + affiliations

Certified Licensing Professional

Listed, Chambers USA: America's Leading Lawyers for Business (2008–2009, 2013–2014)

Listed, Legal Media Group's Life Sciences "Life Sciences Star" – Transactional (2012–2013)

Member, New Jersey Bar Association

Articles Editor, New York University Environmental Law Journal

bar admissions

  • New Jersey
  • Pennsylvania
print profile

David G. Glazer
Partner


Email: dglazer@morganlewis.com
Princeton
502 Carnegie Center
Princeton, NJ 08540-6289
United States of America
Phone: +1.609.919.6624
Fax: +1.609.919.6701

David G. Glazer is a partner in Morgan Lewis's Business and Finance Practice and co-editor of the Morgan Lewis Deskbook for Emerging Growth Life Sciences Companies. Mr. Glazer's practice focuses on advising and representing technology companies, primarily in the life sciences, healthcare, and information technology industries. His clients range from early-stage biotechnology startups to global fortune 100 pharmaceutical companies, including medical device and specialty pharmaceutical companies, and his clients and deal experience extend throughout the United States, Europe, and Asia. Mr. Glazer regularly serves as outside counsel to these companies and counsels them in a variety of different transactions as well as strategic advice. His practice includes negotiation and structuring of licensing and other complex collaborations, corporate partnering arrangements, strategic alliances, mergers and acquisitions, spin-outs, supply and distribution arrangements, co-promotions and joint ventures. These transactions range from early-stage research collaborations to global alliances to develop and commercialize products. He has a solid understanding of the drug and device development and commercialization environment, expertise in early-stage research and development late stage product deals, and specific knowledge of issues in the life sciences industry such as indication, field, and territory splitting. Mr. Glazer works closely with his clients to understand their business and to structure and negotiate transactions to meet a client’s strategic objectives and to find practical solutions to a client’s most complex problems. He advises and counsels private equity, venture capital, and investment banking firms that focus on the life sciences industry.

Mr. Glazer is the author or co-author of a number of articles relating to the life sciences industry including: "Keep One Eye on the Collaboration, And the Other on Exit Events," New Jersey Law Journal, November 22, 2010; "Dividing the Intellectual Property Pie in the Life Sciences Industry," New Jersey Law Journal, April 14, 2011; and, "Changing the Environment for PharmaPharma-Biotech Collaborations, New Jersey LifeSciTech, Q4. In addition, he regularly guest lectures to law students and M.B.A. candidates with respect to licensing in the life sciences industry.

Mr. Glazer is admitted to practice in New Jersey and Pennsylvania and is a Certified Licensing Professional.

Selected Representations

  • Merck in a sale transaction and collaboration with Bayer in which Merck agreed to sell the Merck Consumer Care (MCC) business to Bayer AG pursuant to which Bayer will acquire Merck’s existing over-the-counter business. Merck and Bayer will collaborate to market and develop Bayer’s portfolio of soluble guanylate cyclase modulators
  • BTG in the sale of its brachytherapy business to Eckert & Ziegler
  • Lumiphore in its agreement with Algeta for worldwide license to Lumiphore’s patented chelator technology to be used for cancer therapeutics
  • BTG in its acquisition of the U.S. commercial rights to Wellstat Therapeutics Corporation's product candidate uridine triacetate
  • Merck in its joint venture with Sun Pharmaceutical Industries for innovative formulations
  • Represented a start-up company in spin-out license and technology acquisition from a large pharmaceutical company
  • Lundbeck in its commercial rights agreement with Cephalon to register and commercialize several Cephalon products including Fentora, Provigil, Treanada, Trisenox, Myocet, and Nuvigil in Canada and Latin America
  • BTG in the $180 million acquisition of EKOS Corporation
  • MEI Pharma in its acquisition from S*BIO of the rights toPracinostat, a clinical stage oncology drug
  • NovaDel in its license and distribution agreement with ECR Pharmaceuticals Company to commercialize and manufacture NovaDel’s ZolpiMist and in negotiating its license agreement with Mist Acquisition to manufacture and commercialize NitroMist
  • Eli Lilly in its multi-year, multibillion dollar clinical and research agreements with Covance Inc.
  • LifeNet Health in its acquisition of Northwest Tissue Services from Puget Sound Blood Center
  • Axcan Pharma in its sale of the pharmaceutical products, Photofrin and Photobarr, to Pinnacle Biologics
  • Represented international specialty pharma company in its multi­million dollar transformative manufacturing arrangement, whereby it transitioned the manufacture of several specialty pharmaceutical products to a contract manufacturer
  • Acura Pharmaceuticals in its exclusive license, development and commercialization agreement for North America with King Pharmaceuticals for opioid analgesic products utilizing Acura's patented Aversion® (abuse deterrent) Technology platform
  • NPS Pharmaceuticals in the restructuring and sale of its mGluRs collaboration with AstraZeneca
  • Represented a biotechnology company in negotation of complete supply chain agreements, including with two API manufacturers, two bulk drug manufacturers, two packaging providers, and the supply agreement with its collaboration partner for the finished product in both the United States and Europe
  • Novo Nordisk in its agreement with Sciele Pharma for Sciele to market Prandin® and, upon approval by the US Food and Drug Administration, PrandiMet
  • Recently assisted a European/U.S. company to negotiate clinical trial agreements with more than 25 sites in the U.S. in neuropharm product area.
  • Recently advised a biotechnology company in its master services agreement and clinical trial agreements with an international clinical research organization
  • Axcan Pharma in its exclusive license and development agreement with Cellerix SL of Spain, for the North American rights to Cellerix's biological product using non-embryonic stem-cells
  • Specialty pharmaceutical company in its negotiation with large U.S. pharmaceutical company for the promotion by the U.S. company of the specialty pharmaceutical’s product
  • Schering-Plough in its global collaboration with Novartis to develop and commercialize a once-daily inhaled fixed-dose combination therapy for asthma and COPD

education

  • New York University School of Law, 1997, J.D.
  • Rutgers University, 1994, B.A.